Navigation Links
MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research

SAN DIEGO, April 10 /PRNewswire/ -- MedImmune today announced that researchers will present seven abstracts on the company's oncology portfolio programs at the Annual Meeting of the American Association for Cancer Research, exemplifying the company's long-standing commitment to excellence in oncology research.

"Cancer research has long been a core area of focus at MedImmune and we are proud to share data from our increasingly large oncology portfolio at this year's meeting," said Bahija Jallal, Ph.D., vice president of translational science and head, preclinical oncology.

Investigators will present results from four studies of the novel heat shock protein 90 (Hsp90) inhibitor retaspimycin hydrochloride (also known as IPI-504); two studies of antibodies targeting the CD19 antigen, including MEDI-538 (also known as MT103); and one study of monocyte chemotactic protein-1 (MCP-1).
MedImmune research scheduled to be presented includes:

-- IPI-504, a Novel Hsp90 Inhibitor is Effective in EGFR T790M and

non-T790M Gefitinib-Resistant Lung Cancer Cell Lines (Oral

Presentation: Histone Deacetylase and Heat Shock Protein Inhibitors,

abstract 2450) - Joon O. Park, M.D., Monday, April 14 from 11:55 a.m.

- 12:10 p.m. in Room 24A-C.

-- Pharmaceutical Development of IPI-504, an Aqueous Soluble Analog of

17-AAG and Potent Inhibitor of Hsp90 (Educational Session: From

Chemistry to the Clinic: Pathways for Drug Discovery and Development

- Part 4: Chemical Development: Translating a Potent Agent into a

Registered Product) - James R. Porter, Ph.D., Saturday, April 12 from

4:15 - 4:40 p.m. in Ballroom 20D.

-- IPI-504, a Selective Inhibitor of Hsp90, Exhibits Potent Anti-Tumor

Activity Against Metastatic Melanoma Cell Lines that Harbor B-Raf or

N-Ras Mutations (Poster Session: Pharmacology and Pharmacodynamics,

abstract 4764, poster section 28, board 9) - Jon Cheesebrough, Tuesday,

April 15 from 1:00 - 5:00 p.m. in Exhibit Hall B-F.

-- IPI-504, a Selective Hsp90 Inhibitor is Biologically Active and

Tolerated in Combination with Trastuzumab in Preclinical Models of HER2

Positive Tumor Xenografts (Poster Session: Drug Discovery 2:

Combination Strategies I, abstract 4008, poster section 29, board 6)

- Ching Ching Leow, Ph.D., Tuesday, April 15 from 8:00 a.m. - 12:00

p.m. in Exhibit Hall B-F.

-- Bioavailability, Pharmacodynamic Activity, and Anti-Tumor Efficacy of

the CD19/CD3-Specific BiTE Antibody MEDI-538 (MT103) Delivered

Subcutaneously in Animal Models (Poster Session: Antibodies and

Immunotherapy, abstract 2131, poster section 23, board 6) - Kathy

Mulgrew, Monday, April 14 from 8:00 a.m. - 12:00 p.m. in Exhibit Hall


-- Inhibition of Growth of Human Lymphoma Xenografts with a

Glycoengineered Antibody Specific for the B-Cell Antigen CD19 (Poster

Session: Antibodies and Immunotherapy, abstract 3980, poster section

28, board 8) - Beth K. Ward, Tuesday, April 15 from 8:00 a.m. - 12:00

p.m. in Exhibit Hall B-F.

-- The Characterization of a Potent, Fully Human MCP-1 Antibody In Vitro

and In Vivo (Poster Session: Antibodies, abstract 3986, poster section

28, board 14) - Z. Alexander Cao, Ph.D., Tuesday, April 15 from 8:00

a.m. - 12:00 p.m. in Exhibit Hall B-F.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on cardiovascular/gastrointestinal disease, neuroscience, oncology, infection, respiratory disease and inflammation. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
2. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
3. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
4. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
5. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
6. MedImmune Announces Seven Key Promotions and New Hires
7. MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
8. MedImmune Submits Biologics License Application to FDA for Motavizumab
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. Seneca Valley High School Student Receives Science Award From MedImmune
11. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
Post Your Comments:
(Date:11/24/2015)... ... ... The United States Golf Association (USGA) today announced Dr. Bruce Clarke, of ... since 1961, the USGA Green Section Award recognizes an individual’s distinguished service to the ... of Iselin, N.J., is an extension specialist of turfgrass pathology in the department of ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society for Pharmaceutical Engineering ... premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference took place ... the largest number of attendees in more than a decade. , “The ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... The Academy ... Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the ... last few years. Many AMA members have embraced this type of racing and several ...
(Date:11/24/2015)... 24, 2015  Twist Bioscience, a company focused ... Ph.D., Twist Bioscience chief executive officer, will present ... December 1, 2015 at 3:10 p.m. Eastern Time at The ... --> --> ... Bioscience is on Twitter. Sign up to follow ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
(Date:11/10/2015)... , Nov. 10, 2015 ... behavioral biometrics that helps to identify and verify ... Signature is considered as the secure and accurate ... identification of a particular individual because each individual,s ... accurate results especially when dynamic signature of an ...
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
Breaking Biology News(10 mins):